Durvalumab and tremelimumab in combination with metronomic oral vinorelbine for recurrent advanced cervical cancer: an open-label phase I/II study
Background The MOVIE phase I/II trial (NCT03518606) evaluated the safety and antitumor activity of durvalumab and tremelimumab combined with metronomic oral vinorelbine in patients with advanced tumors. We present the results of the recurrent advanced cervical cancer cohort.Methods Patients received...
Saved in:
| Main Authors: | Pernelle Lavaud, Esma Saada-Bouzid, Renaud Sabatier, Olivia Le Saux, Thibault de la Motte Rouge, Anthony Gonçalves, Elodie Coquan, Jean-Sébastien Frenel, Marta Jiménez, Alice Hervieu, Laurent Mathiot, François Legrand, Claire Cropet, Edith Borcoman, Emmanuelle Charafe |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2025-01-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/13/1/e010708.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Tremelimumab plus durvalumab combined to metronomic oral vinorelbine: Results from the breast cancer cohort of the phase II MOVIE study
by: T. De La Motte Rouge, et al.
Published: (2025-10-01) -
Differential safety profiles of durvalumab monotherapy and durvalumab in combination with tremelimumab in adult patients with advanced cancers
by: Mayur Patel, et al.
Published: (2025-05-01) -
Initial treatment efficacy and safety of durvalumab plus tremelimumab combination therapy in unresectable hepatocellular carcinoma in clinical practice
by: Tetsu Tomonari, et al.
Published: (2024-10-01) -
Adverse drug reaction to tremelimumab and durvalumab in hepatocellular carcinoma patients: an analysis of the food and drug administration adverse event reporting system database
by: Wei Fan Sui, et al.
Published: (2025-08-01) -
First-line durvalumab therapy alone or in combination with tremelimumab for metastatic head and neck squamous cell carcinoma: A cost-effectiveness analysis.
by: Huijuan Li, et al.
Published: (2025-01-01)